메뉴 건너뛰기




Volumn 9, Issue 12, 2014, Pages

Non-vitamin K antagonist oral anticoagulants and the treatment of venous thromboembolism in cancer patients: A semi systematic review and meta-analysis of safety and efficacy outcomes

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; ANTIVITAMIN K; APIXABAN; CYTOCHROME P450 3A4; DABIGATRAN; EDOXABAN; ENOXAPARIN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; NON VITAMIN K ANTAGONIST ORAL ANTICOAGULANT AGENT; QUINIDINE; RIVAROXABAN; UNCLASSIFIED DRUG; VERAPAMIL; VITAMIN K GROUP;

EID: 84915756223     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0114445     Document Type: Article
Times cited : (56)

References (32)
  • 1
    • 0023597478 scopus 로고
    • Pulmonary embolism and thrombophlebitis in the United States, 1970-1985
    • Gillum RF (1987) Pulmonary embolism and thrombophlebitis in the United States, 1970-1985. Am Heart J 114: 1262-1264.
    • (1987) Am Heart J , vol.114 , pp. 1262-1264
    • Gillum, R.F.1
  • 2
    • 35748983238 scopus 로고    scopus 로고
    • Estimated annual numbers of US acute-care hospital patients at risk for venous thromboembolism
    • Anderson FA, Zayaruzny M, Heit JA, Fidan D, Cohen AT (2007) Estimated annual numbers of US acute-care hospital patients at risk for venous thromboembolism. Am J Hematol 82: 777-782. doi:10.1002/ajh.20983.
    • (2007) Am J Hematol , vol.82 , pp. 777-782
    • Anderson, F.A.1    Zayaruzny, M.2    Heit, J.A.3    Fidan, D.4    Cohen, A.T.5
  • 3
    • 35048860791 scopus 로고    scopus 로고
    • Venous thromboembolism (VTE) in Europe. The number of VTE events and associated morbidity and mortality
    • Cohen AT, Agnelli G, Anderson FA, Arcelus JI, Bergqvist D, et al. (2007) Venous thromboembolism (VTE) in Europe. The number of VTE events and associated morbidity and mortality. Thromb Haemost 98: 756-764.
    • (2007) Thromb Haemost , vol.98 , pp. 756-764
    • Cohen, A.T.1    Agnelli, G.2    Anderson, F.A.3    Arcelus, J.I.4    Bergqvist, D.5
  • 4
    • 0037111563 scopus 로고    scopus 로고
    • Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis
    • Prandoni P, Lensing AWA, Piccioli A, Bernardi E, Simioni P, et al. (2002) Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood 100: 3484-3488. doi:10.1182/blood-2002-01-0108.
    • (2002) Blood , vol.100 , pp. 3484-3488
    • Prandoni, P.1    Lensing, A.W.A.2    Piccioli, A.3    Bernardi, E.4    Simioni, P.5
  • 6
    • 0037054040 scopus 로고    scopus 로고
    • Relative impact of risk factors for deep vein thrombosis and pulmonary embolism: A population-based study
    • Heit JA, O'Fallon WM, Petterson TM, Lohse CM, Silverstein MD, et al. (2002) Relative impact of risk factors for deep vein thrombosis and pulmonary embolism: a population-based study. Arch Intern Med 162: 1245-1248.
    • (2002) Arch Intern Med , vol.162 , pp. 1245-1248
    • Heit, J.A.1    O'Fallon, W.M.2    Petterson, T.M.3    Lohse, C.M.4    Silverstein, M.D.5
  • 7
    • 0032559947 scopus 로고    scopus 로고
    • The risk of a diagnosis of cancer after primary deep venous thrombosis or pulmonary embolism
    • Sorensen HT, Mellemkjaer L, Steffensen FH, Olsen JH, Nielsen GL (1998) The risk of a diagnosis of cancer after primary deep venous thrombosis or pulmonary embolism. N Engl J Med 338: 1169-1173. doi:10.1056/NEJM199804233381701.
    • (1998) N Engl J Med , vol.338 , pp. 1169-1173
    • Sorensen, H.T.1    Mellemkjaer, L.2    Steffensen, F.H.3    Olsen, J.H.4    Nielsen, G.L.5
  • 9
    • 79951674716 scopus 로고    scopus 로고
    • Risk of recurrent venous thromboembolism according to malignancy characteristics in patients with cancer-associated thrombosis: A systematic review of observational and intervention studies
    • Louzada ML, Majeed H, Dao V, Wells PS (2011) Risk of recurrent venous thromboembolism according to malignancy characteristics in patients with cancer-associated thrombosis: a systematic review of observational and intervention studies. Blood Coagul Fibrinolysis 22: 86-91. doi:10.1097/MBC.0b013e328341f030.
    • (2011) Blood Coagul Fibrinolysis , vol.22 , pp. 86-91
    • Louzada, M.L.1    Majeed, H.2    Dao, V.3    Wells, P.S.4
  • 10
    • 0034700438 scopus 로고    scopus 로고
    • Prognosis of cancers associated with venous thromboembolism
    • Sorensen HT, Mellemkjaer L, Olsen JH, Baron JA (2000) Prognosis of cancers associated with venous thromboembolism. N Engl J Med 343: 1846-1850. doi:10.1056/NEJM200012213432504.
    • (2000) N Engl J Med , vol.343 , pp. 1846-1850
    • Sorensen, H.T.1    Mellemkjaer, L.2    Olsen, J.H.3    Baron, J.A.4
  • 11
    • 84904726817 scopus 로고    scopus 로고
    • A prospective study on survival in cancer patients with and without venous thromboembolism
    • Agnelli G, Verso M, Mandalà M, Gallus S, Cimminiello C, et al. (2013) A prospective study on survival in cancer patients with and without venous thromboembolism. Intern Emerg Med. doi:10.1007/s11739-013-0985-z.
    • (2013) Intern Emerg Med
    • Agnelli, G.1    Verso, M.2    Mandalà, M.3    Gallus, S.4    Cimminiello, C.5
  • 12
    • 77950794328 scopus 로고    scopus 로고
    • Treatment and secondary prevention of venous thromboembolism in cancer
    • Coleman R, MacCallum P (2010) Treatment and secondary prevention of venous thromboembolism in cancer. Br J Cancer 102 Suppl: S17-23. doi:10.1038/sj.bjc.6605601.
    • (2010) Br J Cancer , vol.102 , pp. S17-S23
    • Coleman, R.1    MacCallum, P.2
  • 13
    • 84888400659 scopus 로고    scopus 로고
    • Vitamin K antagonists in heart disease: Current status and perspectives (Section III). Position paper of the ESC Working Group on Thrombosis - Task Force on Anticoagulants in Heart Disease
    • De Caterina R, Husted S, Wallentin L, Andreotti F, Arnesen H, et al. (2013) Vitamin K antagonists in heart disease: current status and perspectives (Section III). Position paper of the ESC Working Group on Thrombosis - Task Force on Anticoagulants in Heart Disease. Thromb Haemost 110: 1087-1107. doi:10.1160/TH13-06-0443.
    • (2013) Thromb Haemost , vol.110 , pp. 1087-1107
    • De Caterina, R.1    Husted, S.2    Wallentin, L.3    Andreotti, F.4    Arnesen, H.5
  • 14
    • 84888415701 scopus 로고    scopus 로고
    • Cessation of oral anticoagulation in relation to mortality and the risk of thrombotic events in patients with atrial fibrillation
    • Gallego P, Roldan V, Marín F, Romera M, Valdés M, et al. (2013) Cessation of oral anticoagulation in relation to mortality and the risk of thrombotic events in patients with atrial fibrillation. Thromb Haemost 110: 1189-1198. doi:10.1160/TH13-07-0556.
    • (2013) Thromb Haemost , vol.110 , pp. 1189-1198
    • Gallego, P.1    Roldan, V.2    Marín, F.3    Romera, M.4    Valdés, M.5
  • 15
    • 84856802635 scopus 로고    scopus 로고
    • Antithrombotic therapy for VTE disease: Antithrombotic therapy and prevention of thrombosis, 9th ed: American college of chest physicians evidence-based clinical practice guidelines
    • Kearon C, Akl EA, Comerota AJ, Prandoni P, Bounameaux H, et al. (2012) Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 141: e419S-94S. doi:10.1378/chest.11-2301.
    • (2012) Chest , vol.141 , pp. e419S-e494S
    • Kearon, C.1    Akl, E.A.2    Comerota, A.J.3    Prandoni, P.4    Bounameaux, H.5
  • 16
    • 0037775584 scopus 로고    scopus 로고
    • Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer
    • Lee AYY, Levine MN, Baker RI, Bowden C, Kakkar AK, et al. (2003) Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 349: 146-153. doi:10.1056/NEJMoa025313.
    • (2003) N Engl J Med , vol.349 , pp. 146-153
    • Lee, A.Y.Y.1    Levine, M.N.2    Baker, R.I.3    Bowden, C.4    Kakkar, A.K.5
  • 17
    • 84899729145 scopus 로고    scopus 로고
    • Non-vitamin K antagonist oral anticoagulants (NOACs): No longer new or novel
    • Husted S, De Caterina R, Andreotti F, Arnesen H, Bachmann F, et al. (2014) Non-vitamin K antagonist oral anticoagulants (NOACs): No longer new or novel. Thromb Haemost 111. doi:10.1160/TH14-03-0228.
    • (2014) Thromb Haemost , vol.111
    • Husted, S.1    De Caterina, R.2    Andreotti, F.3    Arnesen, H.4    Bachmann, F.5
  • 18
    • 71849117615 scopus 로고    scopus 로고
    • Dabigatran versus warfarin in the treatment of acute venous thromboembolism
    • Schulman S, Kearon C, Kakkar AK, Mismetti P, Schellong S, et al. (2009) Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 361: 2342-2352. doi:10.1056/NEJMoa0906598.
    • (2009) N Engl J Med , vol.361 , pp. 2342-2352
    • Schulman, S.1    Kearon, C.2    Kakkar, A.K.3    Mismetti, P.4    Schellong, S.5
  • 20
    • 84859385808 scopus 로고    scopus 로고
    • Oral rivaroxaban for the treatment of symptomatic pulmonary embolism
    • Büller HR, Prins MH, Lensin AWA, Decousus H, Jacobson BF, et al. (2012) Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med 366: 1287-1297. doi:10.1056/NEJMoa1113572.
    • (2012) N Engl J Med , vol.366 , pp. 1287-1297
    • Büller, H.R.1    Prins, M.H.2    Lensin, A.W.A.3    Decousus, H.4    Jacobson, B.F.5
  • 21
    • 84885618705 scopus 로고    scopus 로고
    • Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism
    • Büller HR, Décousus H, Grosso MA, Mercuri M, Middeldorp S, et al. (2013) Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med 369: 1406-1415. doi:10.1056/NEJMoa1306638.
    • (2013) N Engl J Med , vol.369 , pp. 1406-1415
    • Büller, H.R.1    Décousus, H.2    Grosso, M.A.3    Mercuri, M.4    Middeldorp, S.5
  • 22
    • 84880327613 scopus 로고    scopus 로고
    • Oral apixaban for the treatment of acute venous thromboembolism
    • Agnelli G, Buller HR, Cohen A, Curto M, Gallus AS, et al. (2013) Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med 369: 799-808. doi:10.1056/NEJMoa1302507.
    • (2013) N Engl J Med , vol.369 , pp. 799-808
    • Agnelli, G.1    Buller, H.R.2    Cohen, A.3    Curto, M.4    Gallus, A.S.5
  • 23
    • 84925548115 scopus 로고    scopus 로고
    • Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement
    • Moher D, Liberati A, Tetzlaff J, Altman DG (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J Clin Epidemiol 62: 1006-1012. doi:10.1016/j.jclinepi.2009.06.005.
    • (2009) J Clin Epidemiol , vol.62 , pp. 1006-1012
    • Moher, D.1    Liberati, A.2    Tetzlaff, J.3    Altman, D.G.4
  • 24
    • 68549101842 scopus 로고    scopus 로고
    • The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: Explanation and elaboration
    • Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, et al. (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ 339: b2700.
    • BMJ , vol.339
    • Liberati, A.1    Altman, D.G.2    Tetzlaff, J.3    Mulrow, C.4    Gotzsche, P.C.5
  • 26
    • 0022992740 scopus 로고
    • Meta-analysis in clinical trials
    • DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7: 177-188. doi:10.1016/0197-2456(86)90046-2.
    • (1986) Control Clin Trials , vol.7 , pp. 177-188
    • DerSimonian, R.1    Laird, N.2
  • 27
    • 23044505564 scopus 로고    scopus 로고
    • Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients
    • Schulman S, Kearon C (2005) Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost 3: 692-694. doi:10.1111/j.1538-7836.2005.01204.x.
    • (2005) J Thromb Haemost , vol.3 , pp. 692-694
    • Schulman, S.1    Kearon, C.2
  • 28
    • 0037775584 scopus 로고    scopus 로고
    • Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer
    • Lee AYY, Levine MN, Baker RI, Bowden C, Kakkar AK, et al. (2003) Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 349: 146-153. doi:10.1056/NEJMoa025313.
    • (2003) N Engl J Med , vol.349 , pp. 146-153
    • Lee, A.Y.Y.1    Levine, M.N.2    Baker, R.I.3    Bowden, C.4    Kakkar, A.K.5
  • 29
    • 33846023633 scopus 로고    scopus 로고
    • Long-term low-molecular-weight heparin versus usual care in proximal-vein thrombosis patients with cancer
    • Hull RD, Pineo GF, Brant RF, Mah AF, Burke N, et al. (2006) Long-term low-molecular-weight heparin versus usual care in proximal-vein thrombosis patients with cancer. Am J Med 119: 1062-1072. doi:10.1016/j.amjmed.2006.02.022.
    • (2006) Am J Med , vol.119 , pp. 1062-1072
    • Hull, R.D.1    Pineo, G.F.2    Brant, R.F.3    Mah, A.F.4    Burke, N.5
  • 30
    • 33748498896 scopus 로고    scopus 로고
    • Secondary prevention of venous thromboembolic events in patients with active cancer: Enoxaparin alone versus initial enoxaparin followed by warfarin for a 180-day period
    • Deitcher SR, Kessler CM, Merli G, Rigas JR, Lyons RM, et al. (2006) Secondary prevention of venous thromboembolic events in patients with active cancer: enoxaparin alone versus initial enoxaparin followed by warfarin for a 180-day period. Clin Appl Thromb Hemost 12: 389-396. doi:10.1177/1076029606293692.
    • (2006) Clin Appl Thromb Hemost , vol.12 , pp. 389-396
    • Deitcher, S.R.1    Kessler, C.M.2    Merli, G.3    Rigas, J.R.4    Lyons, R.M.5
  • 31
    • 0037067889 scopus 로고    scopus 로고
    • Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer
    • Meyer G, Marjanovic Z, Valcke J, Lorcerie B, Gruel Y, et al. (2002) Comparison of Low-Molecular-Weight Heparin and Warfarin for the Secondary Prevention of Venous Thromboembolism in Patients With Cancer. Arch Intern Med 162: 1729. doi:10.1001/archinte.162.15.1729.
    • (2002) Arch Intern Med , vol.162 , pp. 1729
    • Meyer, G.1    Marjanovic, Z.2    Valcke, J.3    Lorcerie, B.4    Gruel, Y.5
  • 32
    • 42949091529 scopus 로고    scopus 로고
    • Anticoagulation for the long term treatment of venous thromboembolism in patients with cancer
    • Akl EA, Barba M, Rohilla S, Terrenato I, Sperati F, et al. (2008) Anticoagulation for the long term treatment of venous thromboembolism in patients with cancer. Cochrane database Syst Rev: CD006650. doi:10.1002/14651858.CD006650.pub2.
    • (2008) Cochran database Syst Rev , pp. CD006650
    • Akl, E.A.1    Barba, M.2    Rohilla, S.3    Terrenato, I.4    Sperati, F.5


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.